| Symbol | CTXR |
|---|---|
| Name | CITIUS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11 COMMERCE DRIVE,FIRST FLOOR, CRANFORD, New Jersey, 07016, United States |
| Telephone | +1 908 967-6677 |
| Fax | — |
| — | |
| Website | https://www.citiuspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001506251 |
| Description | Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharmas late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Additional info from NASDAQ: |
Citius Oncology - Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR®Commercialization
Read moreCitius Oncology - Citius Oncology Ships First International Order ofLYMPHIR™ to Europe
Read more(99% Neutral) CITIUS PHARMACEUTICALS, INC. (CTXR) Announces Business Combination
Read moreCitius Pharmaceuticals, Inc. - Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Read moreCitius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Read moreCitius Pharmaceuticals, Inc. - Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Read moreNew Form 424B5 - Citius Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001213900-26-047296 <b>Size:</b> 407 KB
Read more(85% Positive) CITIUS PHARMACEUTICALS, INC. (CTXR) Announces Business Combination
Read moreCitius Oncology - Citius Oncology Provides Commercial Update onLYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05348200 | Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoi… | Phase2 | Hemorrhoids | Completed | 2022-04-22 | 2023-05-17 | ClinicalTrials.gov |
| NCT02689856 | Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II… | Phase2 | Hemorrhoids | Completed | 2015-05-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01871727 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | Phase3 | Persistent or Recurrent Cutaneous T-Cell Lymphoma | Completed | 2013-05-30 | 2021-12-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lidocaine hydrochloride | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Hydrocortisone acetate | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Placebo control | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Hydrocortisone acetate and lidocaine hydrochloride | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Combination - CITI-002 (high dose) | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Combination - CITI-002 (low dose) | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 3 | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 2 | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 1 | Other | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| E7777 9 mcg/kg | Other | Phase PHASE3 | Persistent or Recurrent Cutaneous T-Cell Lymphoma | COMPLETED | NCT01871727 |
| Placebo for ribavirin | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT00925990 |
| ribavirin | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT00925990 |
| Pegylated interferon | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01051921 |
| Ribavirin | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01051921 |
| pegylated interferon | DRUG | Phase PHASE2 | Hepatitis C | TERMINATED | NCT01273064 |
| CTS-1027 | DRUG | Phase PHASE2 | Chronic Hepatitis C Virus Infection | COMPLETED | NCT00570336 |
| Emricasan (25 mg) | DRUG | Phase PHASE2 | Decompensated Cirrhosis | UNKNOWN | NCT03205345 |
| Emricasan (50 mg) | DRUG | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT02686762 |
| Emricasan (5 mg) | DRUG | Phase PHASE2 | Decompensated Cirrhosis | UNKNOWN | NCT03205345 |
| IDN-6556 | DRUG | Phase PHASE2 | Liver Transplantation | COMPLETED | NCT00080236 |
| Placebo oral capsule | DRUG | Preclinical | Decompensated Cirrhosis | TERMINATED | NCT03462576 |
| Emricasan | DRUG | Preclinical | Decompensated Cirrhosis | TERMINATED | NCT03462576 |
| HU6 Capsule | DRUG | Phase PHASE1 | Obese | COMPLETED | NCT05433506 |
| HU6 Tablet | DRUG | Phase PHASE1 | Obese | COMPLETED | NCT05433506 |
| [14C]-HU6 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06325930 |
| HU6 150 mg Capsules x 3 (Total dose = 450 mg) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06486558 |
| HU6 450 mg Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06486558 |
| Placebo | OTHER | Phase PHASE2 | Chronic Hepatitis C Virus Infection | COMPLETED | NCT00570336 |
| HU6 | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04463017 |
| Combination - CITI-002 (high dose) | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Combination - CITI-002 (low dose) | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 3 | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 2 | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Monad 1 | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT05348200 |
| Lidocaine hydrochloride | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Hydrocortisone acetate | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Placebo control | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| Hydrocortisone acetate and lidocaine hydrochloride | DRUG | Phase PHASE2 | Hemorrhoids | COMPLETED | NCT02689856 |
| E7777 9 mcg/kg | DRUG | Phase PHASE3 | Persistent or Recurrent Cutaneous T-Cell Lymphoma | COMPLETED | NCT01871727 |